Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
about
CYP2D6 polymorphisms and their influence on risperidone treatmentRelationship between P-glycoprotein and second-generation antipsychotics.Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphismPopulation pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents.Pharmacogenomic Study Reveals New Variants of Drug Metabolizing Enzyme and Transporter Genes Associated with Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Thai Autism Spectrum Disorder Patients.Psychotropic drug-drug interactions involving P-glycoprotein.Pharmacogenetics of clinical response to risperidone.Pharmacogenomics can improve antipsychotic treatment in schizophrenia.Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.Pharmacogenetics of second-generation antipsychotics.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns.Pharmacokinetic patterns of risperidone-associated adverse drug reactions.Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.Atypical antipsychotics for the treatment of ICU delirium.Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents.Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels.Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.A common polymorphism in the ABCB1 gene is associated with side effects of PGP-dependent antidepressants in a large naturalistic Dutch cohort.Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5.Elevated risperidone serum concentrations during acute inflammation, two cases.Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial
P2860
Q28079227-A17888B7-2E55-4B09-B5C5-B02BC332D6D6Q34208133-C21C5B8D-A99A-4A84-8A7A-5E5A5253AABAQ34429411-F6B8E4FB-CA96-4784-90AD-D0F1719B30BDQ36233555-BAB828B5-9D88-46C7-B30F-D375F986FE31Q37488898-41CE8E6B-1CEF-4BFE-ABE3-3B18E1806190Q38047816-EFB76EC1-B512-427F-9BAA-C65135CA2030Q38074712-E1FCAC54-FB45-432A-A6A5-E213912ECF1FQ38100731-4A793F84-08F3-4FD7-8912-F8846E9A0067Q38154915-CE6C68C5-84B0-4948-A305-BD4781EDB287Q38217628-A8A8161A-5278-4FAD-9E9A-1D233B1CF48DQ38414396-0443A58D-F27A-442A-8340-BEFFC288557EQ39329159-CEABDBDE-ED7B-4D50-B00E-ECAABADE8020Q39633628-B9D5D412-DF73-44F1-B905-1A96042076DEQ39717221-7594EA3A-0B6C-4B8C-9C53-55BC97704D14Q39767297-A133125F-E4FF-426C-8204-BF52A24BE9E8Q40215868-AB62B8DD-907F-49D3-9AA5-2AD2819127AEQ40780592-F5442E04-4ACE-466C-BF1D-D4235F39FD67Q41191596-2C2C0258-A24B-49FD-A0EF-2837FA0973C6Q42717211-DDDE1BC7-0DD2-4D6B-9719-020C6FBC2E41Q46254583-E44BE0A2-3BB9-46F0-ABDB-FFE4EE81C975Q47404372-CCE78DC7-C960-4CC4-958A-A61659DF8E48Q48107672-643A03D7-4727-473E-99C3-CB10FB2C50D8Q48170776-9D29D63D-0EA0-4E95-A2A4-4745DD8DE97FQ48276772-02F56864-5923-4530-A697-B02DA89A91DEQ50933157-F397C636-7EA8-423D-886C-DCEF11621BC5Q50973731-081BA80E-BD52-413B-9459-FB70D3415E43Q57602644-DFAB2E9E-221F-4F66-869E-B869D66950D4
P2860
Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Effect of CYP2D6, CYP3A5, and ...... eridone and its active moiety.
@en
Effect of CYP2D6, CYP3A5, and ...... eridone and its active moiety.
@nl
type
label
Effect of CYP2D6, CYP3A5, and ...... eridone and its active moiety.
@en
Effect of CYP2D6, CYP3A5, and ...... eridone and its active moiety.
@nl
prefLabel
Effect of CYP2D6, CYP3A5, and ...... eridone and its active moiety.
@en
Effect of CYP2D6, CYP3A5, and ...... eridone and its active moiety.
@nl
P2093
P2860
P356
P1476
Effect of CYP2D6, CYP3A5, and ...... eridone and its active moiety.
@en
P2093
Jing Li Duan
Qian Xiang
Yi Min Cui
P2860
P304
P356
10.1177/0091270009347867
P577
2010-03-23T00:00:00Z